The Leading Practice Management and RCM Billing Software for Oncology

A phased plan protects claim flow, posting, and reporting while integrations and staff workflows are validated.

Benchmark denials, drug-waste capture, authorization work, and A/R first. The findings clarify whether a change is worth planning.

The useful work happens before renewal pressure starts. A review of denials, wastage capture, and authorization turnaround gives leadership something concrete to negotiate with, whether or not you change platforms.

Nothing here replaces that expertise. The goal is to remove the manual dose math, portal checking, and spreadsheet tracking that keeps experienced billers off the work only they can do.

Many clinical systems capture the treatment well and stop short of the financial side. Compare what happens to a split-vial dose, a biosimilar substitution, and a step-therapy denial in your current setup. That's usually where the gap shows.

Scope the review around the heaviest burden first, whether that's prior authorization, drug denials, or month-end reporting. A narrow starting point is easier to staff than a full evaluation.

That's the right order. Denial reduction, wastage recapture, authorization turnaround, and staff hours are all measurable against your current numbers before any decision is made.

Reporting gaps are usually the visible end of a data problem upstream. If acquisition cost, contracted rate, and actual payment live in three systems, the report will stay manual no matter who builds it.

Oncology practices typically run an EHR, a clearinghouse, drug purchasing, and assistance programs side by side. The review starts by mapping what each system owns today, so nothing is assumed away.

Legacy balances stay workable through a transition rather than being frozen at go-live. How that's handled is part of the plan, not an afterthought.